Abstract: An apparatus for mixing and dispensing a surgical adhesive having at least two components has a barrel with a central longitudinal axis extending from a first to a second end thereof. The second end includes a nozzle with a discharge port. A rotatable screw conveyor shaft extends through the barrel position along the longitudinal axis. A dispensing element is mounted within the barrel and has a threaded bore for operative engagement with the screw shaft. The dispensing element has a keyway and may freely rotate at the first end of the barrel. A snap element is included to move the dispensing element into engagement with a key on the inner surface of the barrel which prevents the rotation of the dispensing element and causes the dispensing element to move from the first end of the barrel to the second end dispensing the adhesive.
Abstract: A blood washing and plasma separation device and method are disclosed, which utilize lumen-side fed hollow fiber membranes in multiple separation passes in conjunction with countercurrent flow wash injection.
Abstract: Intermediates useful in the synthesis of dihydropyridine platelet activating factor antagonists of the formula ##STR1## where R is phenyl or substituted phenyl; R.sup.3 is lower alkyl; Y is 1,4-phenylene and X is a benzimidazol-1-yl.
Type:
Grant
Filed:
May 1, 1990
Date of Patent:
December 3, 1991
Assignee:
Pfizer Inc.
Inventors:
Melvin Cooper, Michael J. Fray, Kenneth Richardson, John Steele
Abstract: The present invention relates to processes and intermediates for the preparation of spiro-heteroazolones. The latter compounds are useful as aldose reductase inhibitors.
Type:
Grant
Filed:
March 7, 1990
Date of Patent:
November 26, 1991
Assignee:
Pfizer Inc.
Inventors:
Charles W. Murtiashaw, George J. Quallich
Abstract: Apparatus for fixing a fracture of a bone including an elongated body member having a proximal end and a distal end for insertion into the intramedullary canal of the bone; a tab member having at least one aperture to allow for passage of a screw for fastening of the tab member to the bone; and a bolt for selectively removably coupling the tab member to the proximal end of the body member. Preferably, the tab member is of a hollow cylindrical configuration and removably interlocking the first plate member to a second plate member. In another embodiment, the apparatus include a body member for insertion into a bone cavity, the body member having at least one aperture disposed in close proximity to its first end to allow for passage of a screw for fastening the body member to the bone.
Type:
Grant
Filed:
February 2, 1989
Date of Patent:
November 19, 1991
Assignee:
Pfizer Hopsital Products Group, Inc.
Inventors:
Michael W. Chapman, Dana C. Mears, Charles C. Edwards
Abstract: Spiro-heteroazolones are disclosed which are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of complications arising from diabetes. Pharmaceutical compositions containing the spiro compounds and a method of treating diabetic complications are also disclosed.
Abstract: This invention relates to novel 3-(1-substituted-pyrazoyl)-2-oxindole derivatives which are inhibitors of prostaglandin H.sub.2 synthease, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H.sub.2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-(1-substituted-pyrazoyl-2-oxindole derivatives; to methods of inhibiting prostaglandin H.sub.2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel compounds useful as intermediates in the preparation of the 3-(1-substituted-pyrazoyl-2-oxindole derivatives of this invention and to a process for the preparation of the 3-(1-substituted-pyrazoyl)-2-oxindole derivatives.
Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Streptomyces sp. ATCC 53862. This novel antibiotic is useful as an anticoccidial in chickens, in the prevention or treatment of swine dysentery, and as a growth promotant in cattle and swine.
Type:
Grant
Filed:
January 28, 1991
Date of Patent:
November 12, 1991
Assignee:
Pfizer Inc.
Inventors:
Walter P. Cullen, James R. Hauske, Gloria J. Kostek, Hiroshi Maeda, Junsuke Tone
Abstract: Certain derivatives of oxophthalazinyl acetic acids of the formula ##STR1## wherein R.sub.1 is hydroxy or a prodrug group, and R.sub.2 and R.sub.3 are independently hydrogen, fluoro, chloro or trifluoromethyl, except that R.sub.2 and R.sub.3 are not both hydrogen, or a pharmaceutically acceptable base addition salt of a compound of formula I wherein R.sub.1 is hydroxy, are capable of lowering blood uric acid levels in mammals. These oxophthalazinyl acetic acid derivatives are for instance useful for treating gout and gouty arthritis in a mammal .
Abstract: A series of novel 3-mono(substituted methyl)- and 3,3-di(substituted methyl)-2-oxo-indoline-1-alkanoic acid compounds have been prepared, including their lower alkyl esters and unsubstituted amide derivatives, as well as the base salts of said acids with pharmacologically acceptable cations. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical members include those compounds derived from 2-oxo-indoline-1-acetic acid wherein a 3,4-dichlorobenzyl or 3,4-dichloro-.alpha.-methylbenzyl moiety is substituted at 3-position of the molecule. Preferred member compounds include 3-(3,4-dichlorobenzyl)-2-oxo-indoline-1-acetic acid, 5-chloro-3-(3,4-dichlorobenzyl)-2-oxo-indoline-1-acetic acid, 3-(3,4-dichlorobenzyl)-6-methoxy-2-oxo-indoline-1-acetic acid, 3-(3,4-dichlorobenzyl)-6-hydroxy-2-oxo-indoline-1-acetic acid and 3-(3,4-dichloro-.alpha.-methylbenzyl)-2-oxo-indoline-1-acetic acid.
Abstract: Quinolonecarboxylic acid intermediates useful in the preparation of antibacterial 6-fluoro-7-substituted-quinolonecarboxylic aids are prepared from 2-(iodo, bromo or chloro)-3-fluoro-4-(fluoro or chloro)-phenyl carboxylic acid or ester.
Abstract: The bone prosthesis of the present invention comprises a first body member or stem for placement into a bone cavity, such as an intramedullary canal. The body member is configured and dimensioned so as to provide a nonuniform interference press-fit. The apparatus further comprises a second body member or broach for placement into and removal from a bone cavity, the broach configured and dimensioned so as to prepare the bone cavity so as to provide a nonuniform interference press-fit with the stem. The apparatus further comprises a distal sleeve configured and dimensioned so as to be attached to the stem so as to centralize the stem in the bone cavity. The distal sleeve preferably is provided with an interior conical slope and an exterior conical slope on a portion thereof to aid in insertion into the canal. The stem further comprises at least one groove and preferably a plurality of grooves along its corners.
Abstract: Platelet activating factor antagonists of formula (I): ##STR1## wherein R is phenyl or phenyl substituted by one or more substituents selected from nitro, halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, aryl(C.sub.1 -C.sub.4)alkoxy, fluoro(C.sub.1 -C.sub.4)alkoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulphonyl, hydroxy, trifluoromethyl and cyano, or is phenyl fused to a dioxole ring;R.sup.1 and R.sup.2 are each independently H or C.sub.1 -C.sub.6 alkyl, or R.sup.1 and R.sup.2 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl, N-(C.sub.1 -C.sub.4 alkyl)piperazinyl or N-(C.sub.2 -C.sub.4 alkanoyl)-piperazinyl group;R.sup.2 is H or C.sub.1 -C.sub.4 alkyl and R.sup.1 is CN, C.sub.3 -C.sub.7 cycloalkyl, aryl, heteroaryl or a C.sub.1 -C.sub.4 alkyl group substituted by one or more substituents selected from C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.4 alkoxycarbonyl, aryl or heteroaryl;Z is selected from C.sub.1 -C.sub.6 alkoxy, aryl(C.sub.1 -C.sub.
Type:
Grant
Filed:
May 1, 1990
Date of Patent:
November 5, 1991
Assignee:
Pfizer Inc.
Inventors:
Kelvin Cooper, Michael J. Fray, Kenneth Richardson, John Steele
Abstract: 4-Phenyl-1,2,3,4-tetrahydro-1-napthalenamine derivatives have been found useful for the treatment of psychosis, inflammation and as immunosuppressants.
Abstract: Hypoglycemic thiazolidine-2,4-dione derivatives of the formula ##STR1## wherein the dotted line represents a bond or no bond; A and B are each independently CH or N, with the proviso that when A or B is N, the other is CH;X is S, SO, SO.sub.2, CH.sub.2, CHOH or CO;n is 0 or 1;Y is CHR.sup.1 or NR.sup.2, with the proviso that when n is 1 and Y is NR.sup.2, X is SO.sub.2 or CO;Z is CHR.sup.3, CH.sub.2 CH.sub.2, CH.dbd.CH, ##STR2## OCH.sub.2, SCH.sub.2, SOCH.sub.2 or SO.sub.2 CH.sub.2 ; R, R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen or methyl; andX.sup.1 and X.sup.2 are each independently hydrogen, methyl, trifluoromethyl, phenyl, benzyl, hydroxy, methoxy, phenoxy, benzyloxy, bromo, chloro or fluoro; a pharmaceutically-acceptable cationic salt thereof; or a pharmaceutically-acceptable acid addition salt thereof when A or B is N.
Type:
Grant
Filed:
August 14, 1990
Date of Patent:
October 29, 1991
Assignee:
Pfizer Inc.
Inventors:
David A. Clark, Steven W. Goldstein, Gerald F. Holland, Bernard Hulin, James P. Rizzi
Abstract: A device, suitable for use in repairing a lacerated or severed tendon, particularly a hand flexor tendon, having a flat band body with opposite ends of the body designed to anchor connecting sutures. The device also finds applicability in the repair of lacerated or severed ligaments. Also disclosed is a method of repairing a severed tendon by implanting a flat band device suturing together the device and the tendon to effect an anastomosis along approximated ends of the severed tendon. Further disclosed is a method of repairing a lacerated or severed ligament.
Abstract: Substituted tetralins, chromans and related compounds which, by inhibiting 5-lipoxygenase enzyme and/or blocking leukotriene receptors, are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related disease states in mammals, pharmaceutical compositions thereof, a method of treatment therewith, and to intermediates useful in the synthesis thereof.
Type:
Grant
Filed:
August 4, 1989
Date of Patent:
October 22, 1991
Assignee:
Pfizer Inc.
Inventors:
James F. Eggler, Anthony Marfat, Lawrence S. Melvin, Jr.
Abstract: Process for making antiinflammatory 3-aroyl-2-oxindole-1-carboxamides by reductive debromination or deiodination of 3-(bromo- or iodoaroyl)-2-oxindole-1-carboxamides.
Abstract: A series of novel aryloxyalkylamino - and arylaminoalkylamino-pyridine and imidazole compounds have been prepared, including their pharmaceutically acceptable salt, wherein the aryl moiety is further substituted by a sulphamoyl or sulphonylamino group or by a ureido or acylamino group located at the para-position of the ring with respect to the aforesaid alkylamino side chain. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Methods for preparing all these compounds from know starting materials are provided.
Abstract: Antiparasitic compounds of formula (I): ##STR1## The broken line at the 22-23 position representing an optional double bond and either R.sup.1 is H or OH and the double bond is absent or the double bond is present and R.sup.1 is absent; R.sup.2 is optionally substituted phenyl, or a group of formula (II): ##STR2## wherein X is O, S or --CH.sub.2 13 , abc and d are 0-2 and a+b+c+d.ltoreq.5R.sup.3 is H or MeR.sup.4 is H, OH or 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy.The compounds are prepared by fermentation of Streptomyces avermitilis in the presence of an N-alkanoyl cysteamine thioester containing R.sup.2.
Type:
Grant
Filed:
August 29, 1990
Date of Patent:
October 15, 1991
Assignee:
Pfizer Inc.
Inventors:
Christopher J. Dutton, Stephen P. Gibson, Nigel D. A. Walshe